Juan Pablo Sade

Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

Michiel S. van der Heijden, Guru Sonpavde, Thomas Powles et al. · New England Journal of Medicine · 2023 · 462 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

Silke Gillessen, Gerhardt Attard, Tomasz M. Beer et al. · European Urology · 2020 · 395 citations · Full text

Medicine, Oncology, Urology +17

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

Se Hoon Park, Jeffrey C. Goh, Sang Joon Shin et al. · Journal of Clinical Oncology · 2023 · 132 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Silke Gillessen, Alberto Bossi, Ian D. Davis et al. · European Urology · 2022 · 118 citations · Full text

Medicine, Oncology, Urology +16